Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 17 recommandations pour 17 médicaments et 0 équivalent thérapeutique
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
6.4.4. Antihepatitis medicines
  1. Daclatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
    Indications
    Chronic hepatitis C
  2. Daclatasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 60 mg + 400 mg
    Indications
    Chronic hepatitis C
  3. Dasabuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
    Indications
    Chronic hepatitis C
  4. Elbasvir + grazoprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 100 mg
    Indications
    Chronic hepatitis C
  5. Entecavir Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
    Indications
    Chronic hepatitis B
  6. Glecaprevir + pibrentasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
    Indications
    Chronic hepatitis C
  7. Ledipasvir + sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
    Indications
    Chronic hepatitis C
  8. Ombitasvir + paritaprevir + ritonavir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  9. Pegylated interferon alfa (2a) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  10. Pegylated interferon alfa (2b) Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
    Indications
    Chronic hepatitis C
  11. Ravidasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
    Indications
    Chronic hepatitis C
  12. Ribavirin Informations générales
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Chronic hepatitis C
  13. Simeprevir Informations générales
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 150 mg
    Indications
    Chronic hepatitis C
  14. Sofosbuvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg; 200 mg
    Indications
    Chronic hepatitis C
  15. Sofosbuvir + velpatasvir Informations générales
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet
    Indications
    Chronic hepatitis C
  16. Tenofovir alafenamide Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 25 mg
    Indications
    Chronic hepatitis B
  17. Tenofovir disoproxil fumarate Informations générales
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Indications
    Chronic hepatitis B